With CEO search, PhIII study underway, Fulcrum Therapeutics raises $125M from stock offering

Whoever becomes the next CEO of Fulcrum Therapeutics will have $125 million more to work with.

The company is selling off 9.6 million shares of its common stock at a price of $13 per share in a public offering, completely with a 30-day option for the underwriters to purchase up to 1.4 million shares with a closing date of Jan. 23, the company announced Tuesday.